Amarin fish oil capsule shows dramatic benefit for cardiovascular patients, potentially upending market
Amarin fish oil capsule showed dramatic benefits in clinical trials, heralding the possibility of a new way to lower the risk of heart attacks and strokes for some cardiovascular patients.
The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.
In a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin’s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.
Amarin designed its cardiovascular outcomes study, known as REDUCE-IT, hoping to show Vascepa could meet the primary endpoint with a 15 percent risk reduction.
The result announced Monday: a 25 percent risk reduction — highly statistically significant.
“This is absolutely the most significant
